Progress in Neurotherapeutics and Neuropsychopharmacology最新文献

Effect of Methylphenidate in Patients with Acute Traumatic Brain Injury; a Randomized Clinical Trial 哌甲酯治疗急性颅脑损伤的疗效观察随机临床试验

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2008-03-01 DOI: 10.1017/S1748232107000079

Hosseinali Khalili, Kamyar Keramatian

引用次数: 3

New Approaches to Treatment of Schizophrenia by Enhancing N -methyl- D -aspartate Neurotransmission 加强N -甲基- D -天冬氨酸神经传递治疗精神分裂症的新途径

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2008-03-01 DOI: 10.1017/S1748232107000055

G. Tsai

{"title":"New Approaches to Treatment of Schizophrenia by Enhancing N -methyl- D -aspartate Neurotransmission","authors":"G. Tsai","doi":"10.1017/S1748232107000055","DOIUrl":"https://doi.org/10.1017/S1748232107000055","url":null,"abstract":"ABSTRACT Background: There is a great need to develop new antipsychotic agents. In addition to dopaminergic neurotransmission, glutamatergic neurotransmission has been implicated in the pathophysiology of schizophrenia. The most compelling link between glutamatergic N -methyl- d -aspartate (NMDA) neurotransmission and schizophrenia concerns the mechanism of action of the psychotomimetic drug phencyclidine and the dissociative anesthetic, ketamine; both are NMDA antagonists. The psychosis induced by the NMDA antagonists causes not only positive symptoms similar to the action of dopaminergic enhancers but also negative symptoms and cognitive deficits typical of schizophrenia in normal volunteers and worsening of the psychotic symptoms in patients with schizophrenia. Accordingly, enhancing NMDA neurotransmission should benefit the symptoms of schizophrenia. Methods: Most clinical trials were done by the addition of the NMDA-enhancing agents, glycine, d -serine, d -alanine, d -cycloserine and sarcosine to the stable regimens of antipsychotics in double-blind, placebo-controlled designs. Results: When taken together, the trials of NMDA-enhancing agents in patients with chronic schizophrenia receiving stable dose of antipsychotics, the NMDA-enhancing agents were effective in the domains of negative symptoms, cognition, depression, positive symptoms and general psychopathology. The agents also significantly improved extrapyramidal symptoms. No significant side-effects or safety concerns emerged. Interpretation: In addition to testing more lead compounds, dose-finding and long-term trials are required to determine the optimal dose and functional improvement capacity of NMDA receptor agonist. The agents may also be applied to prevention and the treatment for prodromal phases of the illness.","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128532307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Modafinil: A Candidate for Pharmacotherapy of Negative Symptoms in Schizophrenia 莫达非尼:精神分裂症阴性症状药物治疗的候选药物

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2008-03-01 DOI: 10.1017/S1748232107000134

John H. Peloian, J. Pierre

引用次数: 2

Intranasal Zolmitriptan Is Effective and Well Tolerated in Acute Cluster Headache: A Randomized Placebo-Controlled Double-Blind Crossover Study 鼻内佐米曲坦治疗急性丛集性头痛有效且耐受性良好:一项随机安慰剂对照双盲交叉研究

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2008-03-01 DOI: 10.1017/S174823210700016X

E. Cittadini, P. Goadsby

引用次数: 1

A randomized-controlled trial of bilateral rTMS for treatment-resistant depression 双侧rTMS治疗难治性抑郁症的随机对照试验

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2008-03-01 DOI: 10.1017/S1748232107000018

P. Fitzgerald

{"title":"A randomized-controlled trial of bilateral rTMS for treatment-resistant depression","authors":"P. Fitzgerald","doi":"10.1017/S1748232107000018","DOIUrl":"https://doi.org/10.1017/S1748232107000018","url":null,"abstract":"ABSTRACT Background : Antidepressant effects have been demonstrated with both high-frequency left-sided repetitive transcranial magnetic stimulation (rTMS) (HFL-TMS) and low-frequency stimulation to the right prefrontal cortex (LFR-TMS). However, doubts remain about the extent of these reported treatment effects. Design and Methods : The study was a 6 week double-blind randomized sham-controlled trial of sequential bilateral rTMS (SBrTMS) in depression. The method consisted of 3 trains of LFR-TMS of 140 s duration at 1 Hz being applied daily followed immediately by 15 trains of 5 s duration of HFL-TMS at 10 Hz. Sham stimulation was applied using identical parameters, but with the coil angled at 45 degrees from the scalp resting on the side of one wing of the coil. Results : There was a significant difference in response between the two groups at the 2-week time-point ( F (1,25) = 25.5, p F (5,44) = 3.9, p = 0.005). A significant proportion of the active study group met response (11/25) and remission criteria (9/25) by study end compared to the sham group (2 and 0/22). Interpretation : Bilateral rTMS treatment, involving the sequential application of both HFL-TMS and LFR-TMS, has substantial treatment efficacy in patients with treatment-resistant depression. The treatment response is clinically significant following 4–6 weeks of active treatment. Therefore this novel style of bilateral rTMS has the potential to become a substantive clinical intervention, although the study requires replication.","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124151585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

A Randomized Trial Comparing Unilateral Pallidotomy with Bilateral Subthalamic Nucleus Stimulation in PD: Perspectives for Future Implication in Clinical Practice 一项比较PD患者单侧苍白球切开术与双侧丘脑下核刺激的随机试验:对未来临床实践意义的展望

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000036

R. Esselink, R. D. Bie, R. Haan, P. Schuurman, P. Munckhof, J. Speelman

引用次数: 0

A Double-Blind, Randomized Clinical Trial to Assess the Augmentation with Nimodipine of Antidepressant Therapy in the Treatment of “Vascular Depression” 评价尼莫地平增强抗抑郁药物治疗“血管性抑郁症”的双盲随机临床试验

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000103

F. Taragano, P. Bagnati, R. Allegri

引用次数: 2

Can Quality of Life be Improved in Schizophrenia? Results From A Pragmatic, Randomized, Controlled Trial Comparing Olanzapine with First Generation Antipsychotics 精神分裂症患者的生活质量可以改善吗?一项比较奥氮平与第一代抗精神病药物的实用、随机、对照试验的结果

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000176

M. S. Lima, A. Breier, J. Mari

引用次数: 0

Symptomatic Remission in Patients with Bipolar Mania: Results from a Double-Blind, Placebo-Controlled Trial of Risperidone Monotherapy 双相躁狂症患者的症状缓解:利培酮单药治疗的双盲、安慰剂对照试验结果

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000152

S. Gopal, J. Beyer, D. Steffens, M. Kramer

{"title":"Symptomatic Remission in Patients with Bipolar Mania: Results from a Double-Blind, Placebo-Controlled Trial of Risperidone Monotherapy","authors":"S. Gopal, J. Beyer, D. Steffens, M. Kramer","doi":"10.1017/S1748232106000152","DOIUrl":"https://doi.org/10.1017/S1748232106000152","url":null,"abstract":"ABSTRACTBackground: The purpose of this analysis was to compare symptomatic remission rates between risperidone and placebo in a completed randomized controlled trial. Design and Methods: Two hundred ninety (290) adult patients who met DSM-IV criteria for Bipolar I Disorder Manic or Mixed episode were randomized to flexible doses of risperidone or placebo for 3 weeks. An entry Young Mania Rating Scale (YMRS) score of > 20 was required at trial screening and baseline. Time to first onset of remission (as defined as a YMRS score of < 8) was assessed using Cox proportional hazards. Persence or absence of sustained remission was analyzed using logistic regression. Sustained remission was defined as maintaining a YMRS < 8 for the remainder of the trial or until censor. Results: After adjusting for presence of psychosis, baseline YMRS, gender, number of mood cycles in the previous year and treatment,the odds of sustained remission for subjects on risperidone was 5.6 (p < 0.0001). Similarly the adjusted hazard or remission for subjects on rsiperidone was 4.0 (p < 0.0001). Interpretaion: A statistically significant proportion of manic patients receiving risperidone monotherapy achieved symptomatic remission within 3 weeks as compared to placebo.","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121226964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Repetitive Transcranial Magnetic Stimulation: A Novel, Noninvasive Add-on Treatment for Medication-Resistant Depression 重复经颅磁刺激:一种新的、无创的附加治疗药物抵抗性抑郁症

Progress in Neurotherapeutics and Neuropsychopharmacology Pub Date : 2007-03-01 DOI: 10.1017/S1748232106000115

T. Su, Chih-Chia Huang

引用次数: 0